Lung cancer remains one of the leading causes of cancer-related mortality, with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) representing the most prevalent subtypes of non-small ...

When diagnosing lung metastases and second primary lung cancer in patients with head and neck cancer, low-dose CT leads to better sensitivity than chest x-ray but does not lead to improved overall ...

A new systemic nutrition-inflammation index predicted perioperative non-small cell lung cancer outcomes better than current ...

A recent study from Yale University has shed light on how different factors contribute to DNA mutations that drive cancer ...

Lung cancer remains one of the leading causes of cancer-related mortality, with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) representing the most prevalent subtypes of non-small ...

Genetic testing isn’t currently useful in small cell lung cancer. Many mutations involved ... of NSCLC cases are either adenocarcinoma or squamous cell carcinoma, with adenocarcinoma being ...

The Trial in Progress poster includes an overview and study design of the TACTI-004 Phase III evaluating the Company’s MHC Class II agonist, eftilagimod alfa (efti) in combination with MSD’s (Merck & ...

Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National Medical Products Administration (NMPA) for ...

The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in ...

Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...